Alzheimer's

The American Academy of Neurology has submitted a formal national coverage determination reconsideration request to CMS regarding current coverage of amyloid-targeting monoclonal antibodies for Alzheimer’s disease, including Leqembi.

In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.

In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.

Although ankylosing spondylitis correlates with higher rates of Alzheimer’s disease, patients who receive TNF inhibitors are less likely to develop the neurologic disorder, according to data published in Pharmacological Research.

Rural Medicare beneficiaries with Alzheimer’s disease and related dementia had worse outcomes than their urban counterparts, according to results of a retrospective cohort study published in JAMA Network Open.

The prevalence of Alzheimer’s disease is elevated among patients with HIV, and the prevalence of early onset Alzheimer’s disease is even higher among patients who are not being treated with ART, study findings showed.